Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Screening assays evaluate cytotoxicity in earliest stages of drug discovery
July 27, 2012
By: Tim Wright
Editor-in-Chief, Contract Pharma
Ricerca Biosciences introduced two new cellular assay services: Early Safety Screening Cytotoxicity and ImmunoSIGNAL Cytokine Storm Cellular Assay. Early Safety Screening Cytotoxicity is a high-throughput model of cytotoxicity testing that, according to the company, provides a quick and cost-effective option suitable for early in vitro toxicity liability assessment. This assay employs high-resolution cell imaging that allows sensitive detection of cell loss and cell proliferation inhibition. It can run with any of five pre-validated human primary cells, the pre-validated primary cell panel, or cells chosen through collaboration with Ricerca. ImmunoSIGNAL Cytokine Storm Cellular Assay is an in vitro assay that evaluates biologics for their potential to induce cytokine release syndrome, a potentially fatal immune reaction that has been associated with monoclonal antibody therapy. In this assay, compounds are evaluated for their ability to stimulate human peripheral blood mononuclear cells to secrete specific cytokines and chemokines. The assay uses air-dry antibody binding, which produces superior induction of T cell cytokines, inflammatory cytokines, and chemokines. Dr. Usha Warrior, Ricerca technical director of in vitro pharmacology, said, “Bringing these crucial screening assays to the earliest stages of drug discovery with this cost-effective model liberates our clients from having to invest capital and time. Ricerca has the capacity to screen hundreds of compounds a week with these new assays.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !